Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plitidepsin - PharmaMar

Drug Profile

Plitidepsin - PharmaMar

Alternative Names: Aplidin; Aplidine; DDB; Dehydrodidemnin B; PM90001

Latest Information Update: 10 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmaMar
  • Developer Boryung Pharmaceutical; PharmaMar
  • Class Anti-inflammatories; Antineoplastics; Antivirals; Depsipeptides; Lactones
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Peptide elongation factor 1 inhibitors; Protein synthesis inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma; Multiple myeloma; Peripheral T-cell lymphoma

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase III COVID 2019 infections
  • Phase II Non-Hodgkin's lymphoma; T-cell lymphoma; Urogenital cancer
  • No development reported Liposarcoma; Malignant melanoma; Myelofibrosis; Solid tumours
  • Discontinued Leukaemia; Prostate cancer

Most Recent Events

  • 24 Apr 2024 PharmaMar terminates the NEREIDA phase II trial in COVID-2019 infections in Belgium, France, Georgia, Greece, Hungary, Israel, Italy, Poland, Portugal, Spain, and UK (IV, Infusion) due to difficulties in patient recruitment (NCT05705167) (EudraCT2022-002489-34)
  • 24 Apr 2023 Launched for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Australia (IV) before April 2023
  • 20 Apr 2023 PharmaMar expects approval of the phase II NEREIDA trial for COVID-2019 infections in other countries
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top